Oblato Reports the First Patient Enrolment of OKN-007 in the P-I Clinical Trial for Recurrent High-Grade Glioma
Shots:
- The first patient has been enrolled in the P-I clinical trial evaluating OKN-007 in patients with recurrent high-grade glioma in the US
- The purpose of the trial is to assess the safety of an oral dosage form of OKN-007 and to choose a dose for additional clinical trials, providing multiple options for future development by integrating the safety and preliminary efficacy results from this study. Additionally, a dose escalation & PK analysis will also determine in the trial
- The company is also conducting a P-II clinical trial of OKN-007 injectable formulation + temozolomide for recurrent glioblastoma multiforme (GBM) patients at thirteen institutions, including Henry Ford Health System
Ref: prnewswire | Image: Oblato
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
